Parabilis Medicines, Inc. cotiza a 27.48 USD y tiene una capitalización bursátil de $3.4B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable…
| Periodo | 2026-08 |
|---|---|
| Real | $-2.12 |
| Estimado | $-0.24 |
| Sorpresa | -783.3% |
| Métrica | PBLS | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | — | -40.4% | — |
| ROA | — | -32.0% | — |
| Current Ratio | 0.52 | 2.84 | -2.32 |
| Debt / Equity | — | 0.28 | — |